Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares Outstanding
Ratios

Sanofi (SNY) Accumulated Depreciation & Amortization (2016 - 2023)

Sanofi's Accumulated Depreciation & Amortization history spans 8 years, with the latest figure at -$10.2 billion for Q4 2023.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 49.56% to -$10.2 billion in Q4 2023 year-over-year; TTM through Dec 2023 was -$10.2 billion, a 49.56% decrease, with the full-year FY2023 number at -$10.2 billion, down 45.55% from a year prior.
  • Accumulated Depreciation & Amortization hit -$10.2 billion in Q4 2023 for Sanofi, down from -$6.8 billion in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for SNY hit a ceiling of $2.8 billion in Q4 2019 and a floor of -$10.2 billion in Q4 2023.
  • Historically, Accumulated Depreciation & Amortization has averaged -$4.3 billion across 5 years, with a median of -$6.8 billion in 2022.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: crashed 2150.95% in 2021 and later increased 8.93% in 2022.
  • Tracing SNY's Accumulated Depreciation & Amortization over 5 years: stood at $2.8 billion in 2019, then plummeted by 86.87% to $364.8 million in 2020, then crashed by 2150.95% to -$7.5 billion in 2021, then increased by 8.93% to -$6.8 billion in 2022, then tumbled by 49.56% to -$10.2 billion in 2023.
  • Business Quant data shows Accumulated Depreciation & Amortization for SNY at -$10.2 billion in Q4 2023, -$6.8 billion in Q4 2022, and -$7.5 billion in Q4 2021.